Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557071 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL1906847 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL8884583 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL17220701 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL1556471 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| Iodide SCHEMBL9094748 | 0.97 | ACE2 (0.47) | ACE2OPRM1SPHK1LMNATSHR | |
| Hydrochloric Acid SCHEMBL9776519 | 0.97 | ACE2 (0.47) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL1557007 | 0.97 | — | — | |
| SCHEMBL1110063 | 0.92 | ACE2 (0.52) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL3090797 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105985774-B | The application of nanocrystalline-ligand complex, preparation method, printing material and printing material | 纳晶科技股份有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-105985774-A | Nanocrystalline-ligand compound, preparation method of nanocrystalline-ligand compound, printing material and use of printing material | 纳晶科技股份有限公司 | 2016-10-05 | — | — | CN | claimed |
| WO-2023210569-A1 | NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM, AND ORGANIC SEMICONDUCTOR ELEMENT | 東ソー株式会社 | 2023-11-02 | — | — | WO | disclosed |
| EP-3699170-B1 | 2-MERCAPTOETHANOL SYNTHESIS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3699170-A1 | 2-MERCAPTOETHANOL SYNTHESIS | Chevron Phillips Chemical Company LP (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10689333-B1 | 2-mercaptoethanol synthesis | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2020-06-23 | — | — | US | disclosed |
| CN-105985774-B | The application of nanocrystalline-ligand complex, preparation method, printing material and printing material | 纳晶科技股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-105985774-A | Nanocrystalline-ligand compound, preparation method of nanocrystalline-ligand compound, printing material and use of printing material | 纳晶科技股份有限公司 | 2016-10-05 | — | — | CN | disclosed |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2125694-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | Abraxis BioScience, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008064060-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007059118-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | ACE2 3329/4885OPRM1 4442/4885SPHK1 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.